Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

EBCC: European Breast Cancer Conference

2.

Aster Whitefield Hospital, with 506 beds, opened.

3.

For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.

4.

Modified personalized cancer vaccine generates powerful immune response

5.

Knowing about and avoiding bladder cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot